ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

Lexapro and Celexa Lawsuits

Lawsuits against Forest Laboratories claim the antidepressants Celexa and Lexapro caused birth defects and led to suicidal behavior. The company has agreed to millions of dollars in settlements.

Women who took Lexapro while pregnant and gave birth to babies with serious birth defects have filed lawsuits against Forest Laboratories. Other parents sued the company after their children took Celexa and became suicidal.

Federal courts managed lawsuits over the antidepressants in two separate multidistrict litigations. One class action case led to more than 680 people receiving refunds because they had purchased the drugs based on false claims.

As of September 2018, a majority of lawsuits involving Celexa and Lexapro had ended in settlements or were dismissed.

Forest Settles 32 Suicide Lawsuits

Andrew Tradd had been taking Celexa for two years when he hanged himself in 2004. The 13-year-old from Massachusetts died seven days later from a brain injury related to his suicide attempt.

His family filed a lawsuit against Forest Laboratories, claiming the company knew about multiple studies that suggested an increased risk of suicidal behavior for patients taking Celexa and other SSRIs but did nothing to warn physicians or patients of the risk.

The Danish firm that first developed Celexa, H. Lundbeck, had placed suicide warnings on labels for the drug sold in Europe for years prior to Tradd’s death. But the warning did not appear on U.S. labels until the FDA required it in 2004.

Lundbeck had conducted a four-year study that found Celexa was no better than a placebo in treating teens with depression. The results of the trial were known in 2002, but the results were not released until 2004.

Suicidality Warning
Labels for Celexa sold in the U.S. did not warn of a risk for increased suicidal thoughts in children and adolescents until 2004.
Source: U.S. Food and Drug Administration

Tradd wasn’t the only teen alleged to have suffered damaging side effects from Celexa.

Rachel Weiss had been taking Celexa for only nine days when she had a panic attack at school. The 16-year-old threw herself down a stairway and sustained permanent spinal injuries.

Danielle Henrickson, 14, hanged herself in July of 2014 in her parents’ garage. Her parents claimed in a lawsuit that her mental health had worsened after taking Celexa for several weeks.

In 2006, the Judicial Panel on Multidistrict Litigation combined federal Celexa suicide-risk lawsuits in Missouri federal court. The MDL ultimately included 57 cases involving both Celexa and Lexapro.

Allergan Logo

Forest, which is now owned by Allergan, settled the cases involving Tradd, Henrickson and Weiss for undisclosed sums in 2010.

By July 2013, Forest had settled 32 of the cases. The judge had dismissed 11 cases and sent the remaining 13 cases back to their original courts.

Since 2004, the Food and Drug Administration has required a black box warning on antidepressants stating that the medications can cause increased suicidal thoughts in children and adolescents.

Misleading Pediatric Marketing

The second MDL involving Celexa and Lexapro began in 2009 in Massachusetts. United States District Judge Nathaniel M. Gorton oversaw the proceedings.

Lawsuits claimed that Forest wrongly promoted the drugs for pediatric or adolescent patients. The lawsuits also alleged that the company had illegally paid doctors to get them to prescribe the drugs to young patients.

Many of those cases were part of a settlement reached in 2014. The MDL court dismissed the remaining cases. A federal panel dissolved the MDL on Aug. 8, 2018.

The drug manufacturer also paid $313 million in penalties and fines to the federal government for paying doctors to prescribe Celexa and hiding the results of a study that showed the drug was dangerous in children.

MDL Ends in 2018
A multidistrict litigation over Celexa and Lexapro marketing and sales practices ended in 2018 — almost a decade after it began.
Source: Judicial Panel on Multidistrict Litigation

Birth Defect Lawsuits

At end of 2013, Forest Laboratories reported that it was facing at least 182 lawsuits that claimed Celexa and Lexapro led to birth defects including spina bifida, hypoplastic left heart syndrome, anencephaly, craniosynostosis, omphalocele, persistent pulmonary hypotension and club foot. Many of these cases were consolidated in a Missouri state court.

By 2017, the company, now part of Allergan Inc., reported it still faced 179 lawsuits that alleged it failed to warn of birth defect risks. It said it had settled five of the cases in 2016 but did not disclose the amounts of any of the agreements.

Erica Atkinson was among the women who sued. According to court filings, Atkinson took Lexapro during her pregnancy in 2010 and 2011. She gave birth on July 14, 2011, to a baby girl with an atrioventricular canal defect, a life-threatening heart condition that occurs before birth.

Her baby died less than a month later.

State Lawsuits Involving Birth Defects

Twelve women filed lawsuits against Forest in West Virginia Circuit Court in 2015. The women claimed their Celexa or Lexapro ingestion during pregnancy caused their babies’ severe medical problems.

In February 2012, three mothers who had taken Lexapro while they were pregnant filed lawsuits against Forest in St. Louis Circuit Court. The women said they did not know about increased risks until their children were born with birth defects.

Forest tried to move at least 15 lawsuits from New Jersey state courts to federal court in that state. But in 2014, a federal judge sent the cases back to their original state courts.

Forest Settles Missouri Class Action After 2 Months

In January 2014, U.S. District Judge Nathaniel M. Gorton approved a class action for some Missouri plaintiffs, including Missouri residents who had purchased Celexa or Lexapro for a minor between Jan. 1, 1998, and Dec. 31, 2013 and insurance providers.

The plaintiffs claimed Forest misled the parents of the effectiveness of the drug in children. Their lawsuits cited clinical trials that proved Celexa is no more effective than a sugar pill when used to treat children and adolescents.

Class Action Settlement
Forest Laboratories said it would pay up to $10.4 million in refunds.

Gorton certified the Missouri class action under a Missouri consumer protection law. Forest agreed to a settlement two months later.

The exact amount paid to individual patients and their parents is not known. But according to a document filed with the Massachusetts federal court on July 18, 2017, a total of 687 plaintiffs had received more than $4.7 million.

The individual consumers collected roughly $599,000 each, and the remaining $4.1 million went to insurance providers. The filing doesn’t say how many individual consumers were paid.

Additionally, $2.7 million went to a law firm that represented the plaintiffs.

Celexa and Lexapro Pills
Lexapro & Celexa Lawsuit Facts
  1. Injuries Suicide; Birth Defects
  2. Top Settlement More than $7 million to settle a class action
  3. Manufacturer Forest Laboratories

Please seek the advice of a medical professional before making health care decisions.

Elaine Silvestrini
Written By Elaine Silvestrini Writer

Elaine Silvestrini is an award-winning journalist with 30 years of experience covering state and federal court systems. She joined Drugwatch in 2017. Her coverage for Drugwatch has been cited in the CDC’s Public Health Law News and the USA Today Network. Some of her qualifications include:

  • Centers for Disease Control and Prevention certificates in Health Literacy
  • Experience as an assistant investigator for the Federal Public Defender
  • Loyola Law School Journalist Law School Fellowship
Edited By
Emily Miller
Emily Miller Managing Editor

22 Cited Research Articles writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. In Re: Celexa and Lexapro Products Liability Litigation. (2013, July 26) Case: 4:06-md-01636. MDL Pretrial Order for Remanded Cases and Suggestion of Remand. United States District Court Eastern District of Missouri. Retrieved from
  2. In Re: Celexa and Lexapro Products Liability Litigation. (2006, February 17) Case: 4:06-md-01636. Transfer Order. United States District Court Eastern District of Missouri. Retrieved from
  3. In Re: Celexa and Lexapro Marketing and Sales Practices Litigation. (2017, July 18). Case 1:09-md-02067. Petition Regarding the Distribution of Remaining Funds and Closing the QSF for the Missouri Settlement Class. United States District Court for the District of Massachusetts. Retrieved from
  4. In Re: Celexa and Lexapro Marketing and Sales Practices Litigation. (2018, January 26). Case 1:09-md-02067.Memorandum and Order. United States District Court for the District of Massachusetts. Retrieved from
  5. In Re: Celexa and Lexapro Marketing and Sales Practices Litigation. (2017, February 28). Case 1:09-md-02067. Memorandum in Support of Plaintiff’s Second Motion for Class Certification. United States District Court for the District of Massachusetts. Retrieved from
  6. In Re: Celexa and Lexapro Marketing and Sales Practices Litigation. (2017, February 28). Case 1:09-md-02067. Class Plaintiffs’ Memorandum of Law in Support of Joint Motion for Preliminary Approval of Class Settlement and Notice Plan. United States District Court for the District of Massachusetts. Retrieved from
  7. Toutant, C. (2014, July 3). Fed. Judge Kicks 15 Celexa and Lexapro Cases to State Court. Retrieved from
  8. Holleran, K. (2012, February 22). Lexapro maker sued by women claiming children born with birth defects. Retrieved from
  9. Asbury, K. (2015, June 25). 12 Cabell Co. lawsuits blame Lexapro for birth defects. Retrieved from
  10. U.S. Judicial Panel on Multidistrict Litigation. (2018, August 15). MDL Statistics Report. Closed Litigations. Retrieved from
  11. U.S. Judicial Panel on Multidistrict Litigation. (2018, August 15). MDL Statistics Report - Distribution of Pending MDL Dockets by District. Retrieved from
  12. U.S. Department of Justice. (2010, September 15). Drug Maker Forest Pleads Guilty; To Pay More Than $313 Million to Resolve Criminal Charges and False Claims Act Allegations [Press release]. Retrieved from
  13. Winegarner, B. (2014, March 14). Forest Pays Up To $10M In MDL Over Celexa, Lexapro. Retrieved from
  14. FDA approves first generic version of depression drug Lexapro. (2012, March 14). Fox News. Retrieved from
  15. Harris, G. (2009, September 1). Document Details Plan to Promote Costly Drug. The New York Times. Retrieved from
  16. Webb, G. (2009, March 11). Manufacturer of Lexapro - Forest Laboratories - Accused of Fraud. The Legal Examiner. Retrieved from
  17. U.S. Food and Drug Administration. (2012, March 28). FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Retrieved from
  18. Allergan. (2014, July 1). Actavis Completes Forest Laboratories Acquisition. Retrieved from
  19. Bernhard, B. (2014, July 5). Parents can get refunds for some anti-depressant drugs given to kids. Retrieved from
  20. U.S. National Library of Medicine. (2014, November 15). Citalopram. Retrieved from
  21. FDA. (2004, October 15). Suicidality in Children and Adolescents Being Treated With Antidepressant Medications. Retrieved from
  22. Bernhard, B. (2014, July 5). Parents can get refunds for some anti-depressant drugs given to kids. Retrieved from
View All Sources
Who Am I Calling?

Calling this number connects you with a Drugwatch representative. We will direct you to one of our trusted legal partners for a free case review.

Drugwatch's trusted legal partners support the organization's mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.

(888) 645-1617